Plain-English translation of NCT07475403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether immune checkpoint inhibitor-based therapy — a type of immunotherapy — combined with a special urine DNA test can help treat high-risk bladder cancer that cannot be completely removed by standard surgery. The study aims to find out if doctors can use the urine DNA test results to decide when it's safe to stop treatment early, rather than continuing indefinitely, while still keeping patients safe and cancer-free.
High-risk bladder cancers are aggressive and difficult to treat with surgery alone. This trial exists to see if this new treatment approach can be both effective and shorter in duration, reducing the side effects patients experience while maintaining good outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive immunotherapy infusions every 3 weeks for an initial 3 cycles, followed by imaging tests and a bladder procedure to check your response. If the urine DNA test and other assessments show good results, you'll receive 3 more cycles of treatment. Then you'll have repeat testing and biopsies to confirm the cancer has responded well. If all tests are negative, you'll stop treatment and enter a monitoring phase with regular follow-up visits; if tests show remaining cancer, you'll continue with further treatment as recommended by your doctor.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China